EyeBio CEO David Guyer (L) and CSO Anthony Adamis
November 14, 2023 10:40 AM ESTUpdated 12:06 PM
Financing
Startups

Eye­Bio dou­bles the size of its Se­ries A as an­ti-VEGF vet­er­ans seek new ways of treat­ing reti­nal dis­eases

Kyle LaHucik

Senior Reporter

Reti­nal dis­ease biotech Eye­Bio has dou­bled the size of its ini­tial Se­ries A raise from Feb­ru­ary 2022. With an­oth­er $65 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times